Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 18 October 2025 - 24 October 2025

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

As of Oct 24, 2025, RVPH shares trade around $0.57 Investing, after a volatile October run (ranging roughly $0.26–$0.84). The stock has surged ~28% on Oct 23 (to $0.5675 Financialcontent) after a prior drop (–23% on Oct 8 Benzinga). Recent catalysts include completion of a 1-year Phase 3 trial (brilaroxazine OLE) showing robust, sustained efficacy Revivapharma, and plans for an…
24 October 2025
···
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

Key Facts (as of Oct. 23, 2025): Stock Price and Recent Performance AbbVie’s stock has been a standout in 2025. Shares currently hover around $228–$229, up roughly 28% since January and near their highest levels on record Directorstalkinterviews. By comparison, the S&P 500 healthcare index is up only around half that, so AbbVie is outperforming its sector. The stock’s 52-week…
23 October 2025
····
Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

SCNX Stock Soars on Arbli Launch News Scienture’s stock has been on a rollercoaster in late October amid excitement over Arbli’s rollout. The initial catalyst came on October 16, 2025, when the company announced Arbli™ was available through major wholesalers – making it the first FDA-approved liquid losartan on the market ts2.tech. That morning, SCNX shares surged over 30% from…
23 October 2025
····
Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Alkermes Buyout Sparks Rally in AVDL Stock On Oct. 22, 2025, Alkermes announced it would acquire Avadel for $18.50 cash per share plus a $1.50 contingent value right (CVR) tied to an FDA approval for idiopathic hypersomnia, valuing the deal at up to $2.1 billion Prnewswire. The all-cash offer represents roughly a 12% premium to Avadel’s recent trading range. Avadel CEO…
22 October 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Boardroom Shake-Up Spurs Investor Nerves Novo’s stock slide accelerated this week amid a dramatic boardroom conflict. On Oct. 21, the Novo Nordisk Foundation (the company’s controlling shareholder) announced it would remove chair Helge Lund and six other independent directors. A Reuters report noted that this “boardroom coup” came amid disagreement over strategy and a push for “a sharper focus on…
22 October 2025
··
Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Stock Soars on Major Funding News Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnight Marketbeat. In pre-market trading on Oct. 21, NERV stock jumped as much as 160% on the news Gurufocus. The shares opened around $6–7 (up from ~$2.66 prior close) and oscillated…
21 October 2025
···
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

IBIO Stock Price and Recent Volatility As of midday October 21, 2025, iBio’s stock (NASDAQ: IBIO) trades around $0.89 per share Marketbeat. The price has been volatile in recent days. Last week, shares jumped over 20% in pre-market trading on October 17 after Leerink Partners issued a bullish initiation, although the stock later settled near $0.85 by that day’s close…
21 October 2025
···
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Stock Performance Stockanalysis Stockanalysis Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range ($0.51–$3.22 over 52 weeks) Stockanalysis. Trading volume is light (hundreds of thousands of shares), and the stock’s beta (~1.46) indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3…
21 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Stock Soars on Oct 20 Amid Wild October Trading Recursion’s stock is on a rollercoaster ride this month. Early on October 20, RXRX surged ~16–18%, hitting intraday highs near $6.8 Benzinga. The rally comes after shares slid 7.9% on Friday to $5.86 Stockinvest, as traders took profits following a mid-October run-up. Broader market tailwinds helped – the Nasdaq Composite was…
20 October 2025
····
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Stock Price & Recent Performance Before the late-September rally, Pfizer’s stock had been trading lethargically. As one analysis notes, PFE closed around $23.60 on Sept. 26, roughly flat for the year and down ~9% since January ts2.tech. Over the prior 12 months it had fallen about 18%, weighed down by fading COVID sales and patent losses ts2.tech. Its 52-week range…
19 October 2025
····
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai (which is majority-owned by Roche Reuters) to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited…
18 October 2025
···
1 … 40 41 42 43 44 45

Stock Market Today

  • RPC Inc (RES) Stock Surpasses Average Analyst Target Price of $8.17
    January 22, 2026, 8:14 AM EST. Shares of RPC, Inc. (RES) recently traded at $8.32, surpassing the average 12-month analyst target price of $8.17. The target is based on contributions from three analysts, ranging from $7.00 to $10.00 with a standard deviation of $1.61. Analysts have maintained mostly 'Hold' ratings, with a single 'Strong Sell' rating, reflected in an average rating score of 3.67 on a 1 (Strong Buy) to 5 (Strong Sell) scale. This price movement may prompt analysts to adjust targets higher or downgrade valuations depending on fundamental business developments. Investors are encouraged to reassess their positions with RES crossing a key valuation threshold.
Go toTop